Ilaria Del Giudice

Pubblicazioni

Titolo	Pubblicato in	Anno
Sialylation regulates migration in chronic lymphocytic leukemia	HAEMATOLOGICA	2023
Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature.	BRITISH JOURNAL OF HAEMATOLOGY	2023
Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi	HEMASPHERE	2023
Achieving the Cure of Follicular Lymphoma: is it Time to Finalize Treatment Strategies to Reach This Goal in a Subset of Patients?	MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES	2023
Additional lesions identified by genomic microarrays are associated with an inferior outcome in low-risk chronic lymphocytic leukaemia patients	BRITISH JOURNAL OF HAEMATOLOGY	2023
Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet {PCR} improve measurable residual disease monitoring in chronic lymphoid malignancies?	FRONTIERS IN ONCOLOGY	2023
Impact of Sars-CoV-2 Prophylaxis with Tixagevimab-Cilgavimab in High-Risk Patients with B-Cell Malignancies: A Single-Center Retrospective Study	MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES	2023
Early clearance of hairy cell leukaemia in the bone marrow after first‐line treatment with cladribine predicts a favourable outcome	BRITISH JOURNAL OF HAEMATOLOGY	2023
XPO1 mutations identify early-stage CLL characterized by shorter time to first treatment and enhanced BCR signalling	BRITISH JOURNAL OF HAEMATOLOGY	2023
Long‐term benefit of IGHV mutated patients in a real‐life multicenter cohort of FCR‐treated chronic lymphocytic leukemia	HEMATOLOGICAL ONCOLOGY	2023
Measurable residual disease in chronic lymphocytic leukemia. Where do we stand?	LEUKEMIA	2023
Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia	HAEMATOLOGICA	2022
Blast morphology in the diagnostic work-up of Ph-like acute lymphoblastic leukemia	LEUKEMIA & LYMPHOMA	2022
Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study	CANCERS	2022
Circulating cell‐free DNA for target quantification in hematologic malignancies: Validation of a protocol to overcome pre‐analytical biases	HEMATOLOGICAL ONCOLOGY	2022
Impact of anti-SARS-CoV-2 monoclonal antibodies in the management of patients with lymphoma and COVID19: A retrospective study	HEMATOLOGICAL ONCOLOGY	2022
Impact of Anti-Sars-Cov-2 Monoclonal Antibodies in the Management of Patients with Lymphoma and COVID19: A Retrospective Study	BLOOD	2022
P861: SIALOFUCOSYLATED STRUCTURES ENABLE PLATELET BINDING TO MYELOMA CELLS CONFERRING PROTECTION FROM NK-MEDIATED CYTOTOXICITY	HEMASPHERE	2022
Hairy cell leukaemia with low CD103 expression: A rare but important diagnostic pitfall	BRITISH JOURNAL OF HAEMATOLOGY	2022
Early CD49d downmodulation in chronic lymphocytic leukemia patients treated front-line with ibrutinib plus rituximab predicts long-term response	LEUKEMIA & LYMPHOMA	2022

Pubblicazioni

Progetti di Ricerca